Search

Displaying results 1021 - 1030 of 10000 in total
  1. Target

    Splicing factor 1

    go.drugbank.com/bio_entities/BE0009118
    TargetHumans

    Necessary for the ATP-dependent first step of spliceosome assembly. Binds to the intron branch point sequence (BPS) 5'-UACUAAC-3' of the pre-mRNA. May act as transcription repressor

    Synonyms: Zinc finger gene in MEN1 locus
  2. Drug

    Triethylenetetramine

    go.drugbank.com/drugs/DB06824
    ApprovedInvestigational

    [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine].

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Trimebutine

    go.drugbank.com/drugs/DB09089
    ApprovedInvestigational

    Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries. … It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form.

    International brands: Ni Wei FuProducts: Modulon Inj 50mg/5ml
  4. Drug

    Clotrimazole

    go.drugbank.com/drugs/DB00257
    ApprovedInvestigationalVet approved

    It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). … This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s [A174094].

    Mixtures: BAYCUTEN N, BAYCUTEN-NProducts: CLOTRIMAZOLO IG FARMACEUTICI, Terrasil Tinea Treatment MAX
  5. Drug

    Petrolatum

    go.drugbank.com/drugs/DB11058
    ApprovedInvestigational

    It is used as an ointment base, topical protectant, and lubricant.

    Mixtures: CARMEX Multi-Symptom 3 in 1 COLD Sore treatment External Analgesic Skin Protectant, I-defenseCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    Inositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon. … Nicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent.

  7. Drug

    Monopotassium phosphate

    go.drugbank.com/drugs/DB09413
    ApprovedInvestigationalVet approved

    It is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low. … Monopotassium phosphate, MKP, (also potassium dihydrogenphosphate, KDP, or monobasic potassium phosphate), KH2PO4, is a soluble salt of potassium and the dihydrogen phosphate ion.

    Mixtures: NUTRIFLEX PERI IN 2000ML TWIN-FLEX, NUTRIFLEX SPECIAL IN 1000ML TWIN FLEXCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.

  9. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363]

  10. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for … It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules.

    Mixtures: VIRONTAR N COMPRIMIDOS RECUBIERTOS, VIRONTAR N COMPRIMIDOS RECUBIERTOSCategories: Antivirals used in combination for the treatment of HIV infections